Inko Nimmrich

1.4k total citations
24 papers, 1.1k citations indexed

About

Inko Nimmrich is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Inko Nimmrich has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Pathology and Forensic Medicine and 6 papers in Genetics. Recurrent topics in Inko Nimmrich's work include Epigenetics and DNA Methylation (10 papers), Cancer-related gene regulation (7 papers) and RNA modifications and cancer (6 papers). Inko Nimmrich is often cited by papers focused on Epigenetics and DNA Methylation (10 papers), Cancer-related gene regulation (7 papers) and RNA modifications and cancer (6 papers). Inko Nimmrich collaborates with scholars based in Germany, United States and Netherlands. Inko Nimmrich's co-authors include Sabine Maier, Alexander Olek, Nadia Harbeck, Oliver Müller, Ingrid Hoffmann, Christian Piepenbrock, Manfred Schmitt, John W.M. Martens, John A. Foekens and Charles W. Caldwell and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Biochemical Journal.

In The Last Decade

Inko Nimmrich

24 papers receiving 1.1k citations

Peers

Countries citing papers authored by Inko Nimmrich

Since Specialization

Citations

This map shows the geographic impact of Inko Nimmrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Inko Nimmrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Inko Nimmrich more than expected).

Fields of papers citing papers by Inko Nimmrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Inko Nimmrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Inko Nimmrich. The network helps show where Inko Nimmrich may publish in the future.

Co-authorship network of co-authors of Inko Nimmrich

This figure shows the co-authorship network connecting the top 25 collaborators of Inko Nimmrich. A scholar is included among the top collaborators of Inko Nimmrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Inko Nimmrich. Inko Nimmrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial 2017 ·Annals of Oncology ·Petros Christopoulos, Walburga Engel-Riedel, Christian Grohé, Cornelia Kropf-Sanchen, Joachim von Pawel, S Gütz, Jens Kollmeier, Wilfried Eberhardt, D. Ukena, (unknown), Inko Nimmrich, Christian Sieder, Philipp A. Schnabel, Monika Serke, Michael Thomas	53
2	P1.07-003 A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC 2017 ·Journal of Thoracic Oncology ·Christian Grohé, Walburga Engel-Riedel, Cornelia Kropf-Sanchen, (unknown), S Gütz, Jens Kollmeier, Wilfried Eberhardt, Petros Christopoulos, Inko Nimmrich, Christian Sieder, (unknown), Monika Serke, Michael Thomas	1
3	Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – Results of the eLEcTRA trial 2011 ·The Breast ·Jens Huober, Peter A. Fasching, M. Barsoum, Luboš Petruželka, D. Wallwiener, Christoph Thomssen, Toralf Reimer, Stefan Paepke, Hamdy A. Azim, V. Ragosch, E. Kubista, Anne K. Baumgärtner, Matthias W. Beckmann, Christoph May, Inko Nimmrich, Nadia Harbeck	171
4	Multicenter Study Using Paraffin-Embedded Tumor Tissue Testing PITX2 DNA Methylation As a Marker for Outcome Prediction in Tamoxifen-Treated, Node-Negative Breast Cancer Patients 2008 ·Journal of Clinical Oncology ·Nadia Harbeck, Inko Nimmrich, Arndt Hartmann, Jeffrey S. Ross, Tanja Čufer, Robert Grützmann, Glen Kristiansen, Angelo Paradiso, Oliver Hartmann, (unknown), John W.M. Martens, (unknown), (unknown), Volkmar Müller, Karin Milde‐Langosch, Jörg Nährig, John A. Foekens, Sabine Maier, Manfred Schmitt, Ralf Lesche	83
5	DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group 2007 ·European Journal of Cancer ·Sabine Maier, Inko Nimmrich, Thomas Koenig, Serenella Eppenberger‐Castori, (unknown), Angelo Paradiso, Frédérique Spyratos, Christoph Thomssen, Volkmar Mueller, Jörg Nährig, Francesco Schittulli, Ronald Kates, Ralf Lesche, (unknown), (unknown), Almuth Marx, John W.M. Martens, John A. Foekens, Manfred Schmitt, Nadia Harbeck	93
6	DNA hypermethylation of PITX2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients 2007 ·Breast Cancer Research and Treatment ·Inko Nimmrich, Anieta M. Sieuwerts, Marion E. Meijer‐van Gelder, (unknown), Joan Bolt‐de Vries, Nadia Harbeck, Thomas Koenig, Oliver Hartmann, (unknown), Dimo Dietrich, Viktor Magdolen, Henk Portengen, Maxime P. Look, Jan G.M. Klijn, Ralf Lesche, Manfred Schmitt, Sabine Maier, John A. Foekens, John W.M. Martens	85
7	Association of DNA Methylation of Phosphoserine Aminotransferase with Response to Endocrine Therapy in Patients with Recurrent Breast Cancer 2005 ·Cancer Research ·John W.M. Martens, Inko Nimmrich, Thomas Koenig, Maxime P. Look, Nadia Harbeck, Fabian Model, (unknown), Joan Bolt‐de Vries, Anieta M. Sieuwerts, Henk Portengen, Marion E. Meijer‐van Gelder, Christian Piepenbrock, Alexander Olek, Heinz Höfler, Marion Kiechle, Jan G.M. Klijn, Manfred Schmitt, Sabine Maier, John A. Foekens	102
8	Methylation discriminators in NSCLC identified by a microarray based approach 2005 ·International Journal of Oncology ·John K. Field, Triantafillos Liloglou, (unknown), M. Bürger, (unknown), (unknown), Inko Nimmrich, Sabine Maier	31
9	DNA Methylation Markers – an Opportunity to Further Individualize Therapy in Breast Cancer? 2005 ·Personalized Medicine ·Sabine Maier, Ralf Lesche, Inko Nimmrich, Florian Eckhardt, (unknown), Achim Plum	1
10	Differential DNA Methylation of Gene Promoters in Small B-Cell Lymphomas 2005 ·American Journal of Clinical Pathology ·Juyuan Guo, Matthias Burger, Inko Nimmrich, Sabine Maier, (unknown), (unknown), (unknown), Farahnaz Rahmatpanah, (unknown), Huidong Shi, Kurt Berlin, Tim H-M. Huang, Charles W. Caldwell	21
11	Distinction of acute lymphoblastic leukemia from acute myeloid leukemia through microarray-based DNA methylation analysis 2004 ·Annals of Hematology ·Christian W. Scholz, Inko Nimmrich, Matthias Burger, (unknown), (unknown), Wolfgang Ludwig, Sabine Maier	20
12	DNA methylation profile predicts risk of recurrence in tamoxifen-treated, node-negative breast cancer patients 2004 ·Journal of Clinical Oncology ·Sabine Maier, Inko Nimmrich, Almuth Marx, Serenella Eppenberger‐Castori, Fritz Jaenicke, Angelo Paradiso, F. Spyratos, John A. Foekens, (unknown), Nadia Harbeck	1
13	The androgen receptor gene is preferentially hypermethylated in follicular non-Hodgkin's lymphomas. 2003 ·PubMed ·(unknown), Chuan‐Mu Chen, Pearlly S. Yan, (unknown), Huidong Shi, (unknown), Inko Nimmrich, Sabine Maier, Kurt Berlin, Charles W. Caldwell	32
14	Epigenomics: Genome-Wide Study of Methylation Phenomena 2002 ·Current Issues in Molecular Biology ·Karen Novik, Inko Nimmrich, (unknown), Sabine Maier, Christian Piepenbrock, Alexander Olek, Stephan Beck	106
15	Oligonucleotide‐based microarray for DNA methylation analysis: Principles and applications 2002 ·Journal of Cellular Biochemistry ·Huidong Shi, Sabine Maier, Inko Nimmrich, Pearlly S. Yan, Charles W. Caldwell, Alexander Olek, Tim H.‐M. Huang	80
16	The novel ependymin related gene UCC1 is highly expressed in colorectal tumor cells 2001 ·Cancer Letters ·Inko Nimmrich, Silke Erdmann, (unknown), (unknown), (unknown), Sebastian Hentsch, Ingrid Hoffmann, (unknown), Werner Hoffmann, Oliver Müller	47
17	Seven genes that are differentially transcribed in colorectal tumor cell lines 2000 ·Cancer Letters ·Inko Nimmrich, Silke Erdmann, (unknown), (unknown), Sebastian Hentsch, Mary Pat Moyer, Ingrid Hoffmann, Oliver Müller	54
18	A β-catenin mutation in a sporadic colorectal tumor of the RER phenotype and absence of β-catenin germline mutations in FAP patients 1998 ·Genes Chromosomes and Cancer ·Oliver Müller, Inko Nimmrich, (unknown), Waltraut Friedl, Ingrid Hoffmann	22
19	A beta-catenin mutation in a sporadic colorectal tumor of the RER phenotype and absence of beta-catenin germline mutations in FAP patients. 1998 ·PubMed ·Oliver Müller, Inko Nimmrich, (unknown), Waltraut Friedl, Ingrid Hoffmann	25
20	Loss of the PLA2G2A gene in a sporadic colorectal tumor of a patient with a PLA2G2A germline mutation and absence of PLA2G2A germline alterations in patients with FAP 1997 ·Human Genetics ·Inko Nimmrich, Waltraut Friedl, Roland Kruse, (unknown), Sebastian Hentsch, (unknown), G Winde, Oliver Müller	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact